In isolated perfused rabbit mandibular glands undergoing stimulation with 0.8 microM acetylcholine, replacement of HCO3- with acetate (25 mM) increased fluid secretion by more than 100%. Other short-chain fatty acids, except for propionate, had a similar effect. We focused our further studies on acetate, and in order to find out the cause of its stimulatory effect we investigated whether acetate itself was transported. In the absence of any other transportable anions 25 mM acetate supported secretion at the same rate as 25 mM HCO3- or 25 mM Cl-, i.e. 20% of the control rate. In solutions containing acetate as the only major anion (146 mM), fluid secretion was maintained at about 50% of the control rate. Amiloride (1 mM) inhibited this secretion by about 90%. In glands perfused with acetate/Cl- solutions, when the stimulatory effect was normally observed, amiloride (1 mM) inhibited secretion by 50-60% and SITS (0.1 mM) had no effect. Probenecid reversibly inhibited 75% of secretion in these glands, but it also inhibited 92% of secretion in glands perfused without any acetate. Interestingly, the acetate effect was abolished in glands stimulated with a higher concentration of acetylcholine (80 microM). Results of this study suggest that acetate can be transported by salivary endpieces and that this transport involves an amiloride-sensitive Na+-H+ antiport. We postulate that acetate may in addition have some regulatory or modifier role in salivary secretion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF00585628 | DOI Listing |
Int Med Case Rep J
January 2025
Department of Neurology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, People's Republic of China.
Background: Coexistence of autoimmune encephalitis (AE) with multiple autoantibodies is of particular concern because overlying antibodies may cause variation of clinical manifestations. Coexistence of anti-glutamic acid decarboxylase (GAD) and anti-Gamma-aminobutyric acid-α-receptor (GABAAR) antibodies in AE was rare.
Case Presentation: A 44-year-old female patient presented to our hospital due to cognitive decline for 4 years, seizures, slowed speech and depression for 2 months.
Front Pharmacol
January 2025
School of Pharmacy, Xinjiang Medical University, Urumchi, China.
Background: In the Kazakh community of Xinjiang, China, fermented camel milk has been traditionally used to manage diabetes. This study evaluates the effects of composite probiotics derived from fermented camel milk (CPCM) on metabolic disturbances in a rat model of Type 2 diabetes (T2DM).
Methods: T2DM was induced in Wistar rats using streptozotocin.
Front Neurosci
January 2025
Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL, United States.
Introduction: Posttraumatic stress disorder (PTSD) is a debilitating disorder characterized by intrusive memories, avoidance, negative thoughts and moods, and heightened arousal. Many patients also report gastrointestinal symptoms. Cognitive behavioral therapy (CBT) is an evidence-based treatment approach for PTSD that successfully reduces symptoms.
View Article and Find Full Text PDFISME Commun
January 2025
Key Laboratory of Water and Sediment Sciences, Ministry of Education, Department of Environmental Engineering, Peking University, Beijing 100871, China.
Rivers serve important functions for human society and are significantly impacted by anthropogenic nutrient inputs (e.g. organic and sulfur compounds).
View Article and Find Full Text PDFClin Ophthalmol
January 2025
Harvard Eye Associates, Laguna Hills, CA, USA.
Purpose: To assess real-world efficacy and safety of standalone travoprost intracameral implant (iDose TR) implantation by a US glaucoma surgeon in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Methods: This non-randomized, retrospective, unmasked, consecutive case series included all cases of standalone iDose TR implantation from a single US glaucoma surgeon since the product's approval by the US Food and Drug Administration (FDA) in December 2023. Patients were pseudophakic, had OAG or OHT, and had undergone prior SLT and/or bimatoprost intracameral implant injection (Durysta).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!